0O
0OT.F Ocular Therapeutix Inc
- Market cap
- EUR 1.28B
- P/E
- -
- P/B
- 3.27x
- ROE
- -79.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0OT.F undervalued?
Graham numberThe Graham number of Ocular Therapeutix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ocular Therapeutix Inc fundamental analysis
No fundamental analysis for Ocular Therapeutix Inc yet.
Ocular Therapeutix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravi…
Full company profileOcular Therapeutix Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ocular Therapeutix Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.89M | 1.92M | 1.99M | 4.23M | 17.4M | 43.5M | 51.5M | 58.4M | 63.7M | 52.0M | 49.5M |
| Gross Profit | 1.44M | 1.47M | 1.53M | 1.90M | 15.3M | 39.1M | 47.0M | 53.2M | 58.1M | 45.4M | 43.1M |
| Operating Income | -43.3M | -61.9M | -59.1M | -85.8M | -62.8M | -78.0M | -78.7M | -82.4M | -172M | -270M | -364M |
| EBITDA | - | -59.9M | -56.0M | -77.7M | -146M | 2.54M | -64.0M | -66.4M | -176M | -250M | -331M |
| Net Income | -44.7M | -63.4M | -60.0M | -86.4M | -156M | -6.55M | -71.0M | -80.7M | -194M | -266M | -350M |
| EPS | - | -2.14 | -1.44 | -1.72 | -2.05 | -0.09 | -0.92 | -0.70 | -1.23 | -1.23 | -1.59 |
| Balance Sheet | |||||||||||
| Total Assets | 74.9M | 55.4M | 73.0M | 78.7M | 262M | 205M | 149M | 252M | 458M | 808M | 606M |
| Total Liabilities | 22.9M | 29.3M | 37.2M | 82.4M | 186M | 117M | 114M | 161M | 143M | 154M | 165M |
| Shareholders' Equity | 52.0M | 26.1M | 35.9M | -3.63M | 76.1M | 88.0M | 35.4M | 91.1M | 315M | 654M | 441M |
| Cash & Short-term Investments | 32.9M | 41.5M | 54.1M | 54.4M | 228M | 164M | 102M | 196M | 392M | 737M | 531M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.0M | -50.5M | -49.2M | -77.6M | -53.6M | -65.6M | -59.6M | -70.2M | -135M | -205M | -265M |
| Capital Expenditure | 1.92M | 8.25M | 1.89M | 2.24M | 841K | 1.19M | 3.72M | 6.09M | 1.29M | 12.0M | 14.7M |
| Free Cash Flow | - | -58.7M | -51.1M | -79.8M | -54.4M | -66.7M | -63.3M | -76.3M | -136M | -217M | -280M |
| Ratios | |||||||||||
| ROE | -86.0% | -242.4% | -167.2% | - | -204.5% | -7.4% | -200.8% | -88.6% | -61.4% | -40.6% | -79.3% |
| ROA | -59.7% | -114.4% | -82.1% | -109.7% | -59.4% | -3.2% | -47.6% | -32.0% | -42.3% | -32.9% | -57.7% |
| Net Profit Margin | -2,369.0% | -3,296.2% | -3,014.0% | -2,043.3% | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -511.9% | -706.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ocular Therapeutix Inc dividends
Ocular Therapeutix Inc has not paid dividends in the last 9 fiscal years.
Who owns Ocular Therapeutix Inc
- Insiders 0.90%
- Institutions 95.80%
- Public & others 3.30%
- Shares outstanding 220M
- Free float 185M
Ocular Therapeutix Inc company profile
- Company name
- Ocular Therapeutix Inc
- Ticker
- 0OT.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 325
- Fiscal year end
- December
- Address
- 14 Crosby Drive, Bedford, MA, United States, 01730
- Phone
- 781 357 4000
- Website
- ocutx.com
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix Inc management
10- Dr. Pravin U. Dugel M.D.Executive Chairman, President & CEO · born 1964
- Mr. Donald Notman Jr.Chief Operating Officer (Leave of Absence)
- Mr. Steve MeyersChief Commercial Officer
- Dr. Nadia K. Waheed M.D., M.P.H.Chief Medical Officer · born 1977
- Mr. Jason RobinsCFO & Principal Accounting Officer · born 1977
- Dr. Peter K. Jarrett Ph.D.Chief Technical Officer · born 1957
- Dr. Jeffrey S. Heier M.D.Chief Scientific Officer · born 1961
- Mr. William S. Slattery Jr.Vice President of Investor Relations
- Mr. Todd D.C. Anderman J.D.Chief Legal Officer & Corporate Secretary · born 1982
- Mr. William H. Ransone IIVice President of Global Sales & Marketing